Recent advances in immuno-oncol- ogy and its application to urological cancers. BJU Int 2016; 118: 506-514.Mataraza JM, Gotwals P. Recent advances in immuno-oncology and its application to urological cancers. BJU Int. 2016;118: 506-14....
they are more labor-intensive and have lower throughput than pooled arrays; thereby, studies extensively apply pooled screens for discovery. CRISPR has unraveled several molecules in the immune-oncology field. Therefore, we list the recent findings...
Recent advances in immuno-oncology have the potential to transform the practice of medical oncology. Antibodies directed against negative regulators of T-cell function (checkpoint inhibitors), engineered cell therapies and innate immune stimulators, such as oncolytic viruses, are effective in a wide ...
which are highly heterogeneous, CD8 + T cells can be predictive markers for the efficacy of immunotherapy and that differentiating these cells into subsets can provide more precise guidance for predictions
The incorporation of checkpoint inhibitors into the treatment armamentarium of oncologic therapeutics has revolutionized the course of disease in many canc
Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care Spotlight - In-person and virtual events just for HCPs CME Opportunities Choose Specialty
For oncology patients, the immune system tends to present poor co-stimulation and high co-suppression in TME. Moreover, T cells generally develop phenotypic and functional states that are difficult to exert antitumor effects, such as poor proliferation and severe apoptosis [42]. Relevant molecules ...
This Review discusses the major advances and changes made over the past 3 years to our understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the field has gained insight into how various molecular modules of the CAR in
“cytotoxicity”). This precision medicine approach leads to higher response rates and increased chances of remission, which is nothing short of revolution in the oncology field. It is especially remarkable considering that Dr. Rosenberg discovered TIL’s cytotoxicity ~ 40 years ago without many ...
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy ArticleOpen access03 April 2020 Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons Introduction The cancer burden is a crucial global public health problem, which exerts tremendous physical...